Objectives:

1.Review the pathogenesis and immunogenicity of Classical Hodgkins Lymphoma

2. Discuss the current choices for salvage therapy in first relapse

3. Identify new strategies for salvage by incorporating immunotherapy and brentuximab vedotin 

 

 

 

Session date: 
02/27/2017 - 12:00pm to 1:00pm CST
Location: 
UCMC KCBD
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Andrew Hantel & Anu Neerukonda